These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21933695)

  • 1. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies.
    Dalgleish AG
    Vaccine; 2011 Nov; 29(47):8501-5. PubMed ID: 21933695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-small-cell lung carcinoma vaccines in clinical trials.
    Rossi A; Maione P; Schettino C; Bareschino MA; Sacco PC; Ambrosio R; Barbato V; Zeppa R; Palazzolo G; Gridelli C
    Expert Rev Vaccines; 2011 Jun; 10(6):887-97. PubMed ID: 21692707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell based cancer vaccines: regulatory and commercial development.
    Copier J; Ward S; Dalgleish A
    Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.
    Hege KM; Jooss K; Pardoll D
    Int Rev Immunol; 2006; 25(5-6):321-52. PubMed ID: 17169779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
    Mazumdar M; Fazzari M; Panageas KS
    Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic cancer vaccines.
    Srivastava PK
    Curr Opin Immunol; 2006 Apr; 18(2):201-5. PubMed ID: 16464565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Special report: vaccines for the treatment of prostate cancer.
    Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182
    [No Abstract]   [Full Text] [Related]  

  • 11. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
    Mosolits S; Nilsson B; Mellstedt H
    Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal cancer vaccines in clinical trials.
    Speetjens FM; Zeestraten EC; Kuppen PJ; Melief CJ; van der Burg SH
    Expert Rev Vaccines; 2011 Jun; 10(6):899-921. PubMed ID: 21692708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer vaccines: will we ever learn?
    Johnson RS; Walker AI; Ward SJ
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):67-74. PubMed ID: 19105708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
    Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
    Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.
    Freidlin B; Breathnach OS; Johnson BE
    Clin Cancer Res; 2003 Mar; 9(3):917-22. PubMed ID: 12631588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current approaches in ovarian cancer vaccines.
    Reinartz S; Wagner U
    Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines.
    Sasada T; Komatsu N; Suekane S; Yamada A; Noguchi M; Itoh K
    Eur J Cancer; 2010 Jun; 46(9):1514-9. PubMed ID: 20413296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccines for prostate cancer.
    Cha E; Fong L
    Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.